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Background: Lysine-specific demethylase1 (LSD1) is a nuclear protein which belongs to the aminooxidase-enzymes
playing an important role in controlling gene expression. It has also been found highly expressed in several human
malignancies including breast carcinoma. Our aim was to detect LSD1 expression also in pre-invasive neoplasias of
the breast. In the current study we therefore analysed LSD1 protein expression in ductal carcinoma in situ (DCIS) in
comparison to invasive ductal breast cancer (IDC).
Methods: Using immunohistochemistry we systematically analysed LSD1 expression in low grade DCIS (n = 27),
intermediate grade DCIS (n = 30), high grade DCIS (n = 31) and in invasive ductal breast cancer (n = 32). SPSS version
18.0 was used for statistical analysis.
Results: LSD1 was differentially expressed in DCIS and invasive ductal breast cancer. Interestingly, LSD1 was
significantly overexpressed in high grade DCIS versus low grade DCIS. Differences in LSD1 expression levels were
also statistically significant between low/intermediate DCIS and invasive ductal breast carcinoma.
Conclusions: LSD1 is also expressed in pre-invasive neoplasias of the breast. Additionally, there is a gradual
increase of LSD1 expression within tumour progression from pre-invasive DCIS to invasive ductal breast carcinoma.
Therefore upregulation of LSD1 may be an early tumour promoting event.
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LSD1 (Lysine-specific demethylase 1) is a key enzyme in
posttranslational histone modification [1]. Histone modifi-
cations including acetylation, methylation, phosphorylation
and ubiquitination play an important role in structural
changes of chromatin [2,3]. Chromatin modifying activities
are dynamically regulated processes and form epigenetic
marks on the histone substrate. Thus, enzymes and espe-
cially LSD1 are involved in epigenetic gene deregulation
and initiate tumourgenesis [3-5]. So far little is known on
the in vivo biochemical mechanism by which LSD1* Correspondence: bnuran@hotmail.com
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reproduction in any medium, provided the oroverexpression is linked to neoplastic cell proliferation. Dis-
covered by in vitro data it was shown that LSD1 interfers
to G2-M phase cell-cycle and promotes cell proliferation
[6]. LSD1 is localised in the nucleus and characterised by a
C-terminal amino oxidase domain (AOD) and by an N-
terminal domain. The catalytic centre of LSD1 is the Flavin
Adenin Dinucleotide-dependent AOD region. This highly
specific catalytic domain leads to demethylation of mono-
or dimethylated lysine (Lys4) of histone 3 (H3) [5,7].
LSD1 has been analysed in several human tumour en-
tities. It has been shown to be overproduced in prostate
cancer [8,9], neuroblastoma [10], lung, colorectal and
bladder cancer [11,12]. Furthermore, LSD1 expression
has also been investigated in invasive breast carcinoma.
Lim et al. [13] showed a significant positive correlation
between overexpression of LSD1 and negative oestrogentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inverse correlation between high LSD1 expression levels
and low progesterone receptor status. Other histopatho-
logical data like tumour size (pT1-pT4), nodal status
and human epidermal growth factor receptor (HER 2)
status reached no significant correlation with LSD1 ex-
pression. However in consideration of the fact that
breast carcinoma with positive steroid hormone receptor
status responds to endocrine treatment [14] and there-
fore reveals a better prognosis, Lim et al. supposed that
upregulation of LSD1 and its correlation with negative
oestrogen receptor status could be a biomarker for ag-
gressive tumour biology in breast cancer.
Consistent with its tumour promoting role, the specifi-
city of posttranslational modification conferred by LSD1
has been investigated by Bradley et al. [15]. They ana-
lysed human mammary epithelial cell lines after carcino-
gen exposure and examined equal levels of histone H3
total protein and histone H4, but significantly decreased
levels of mono-methyl histone H3 (Lys4) compared with
control groups which were not treated. They pointed
out that downregulation of histone H3 (Lys4) was
related to LSD1 upregulation after carcinogen treatment.
In addition accumulated levels of carcinogen exposure
were related to accumulated levels of LSD1 expression
compared to control human mammary epithelial cell
lines. Thus increased LSD1 expression was assumed to
be an early step in breast cancer development.
Surprisingly, LSD1 has not been studied in pre-
invasive breast cancer lesions, so far. To the best of our
knowledge, this is the first study to analyse LSD1 protein
expression in pre-invasive breast neoplasias. We system-
atically examined LSD1 expression in low, intermediate
and high grade ductal carcinoma in situ in comparison
to invasive ductal carcinoma.
Methods
Tissue specimens
Paraffin embedded breast cancer specimens were selected
from the tumour data bank of the Institute of Pathology,
University of Bonn. Patients` age ranged from 27 to 88 years
with a median of 56 years. An experienced surgical path-
ologist evaluated haematoxylin-eosine stained slides of all
specimens. Histologically all DCIS lesions were graded
according to established criteria by the World Health Or-
ganisation (WHO) [16]. These are based on nuclear grad-
ing, necrosis, microcalcification and architecture. DCIS was
classified in low grade (n=27), intermediate grade (n=30)
and high grade (n=31) and was compared with invasive
ductal breast carcinoma specimens (n=32) (Table 1).
All 120 patients gave informed consent for further
analysis of their tissue for research purposes and the In-
structional Review Board of the participating centre
approved the study.LSD1 immunohistochemistry
LSD1 immunohistochemistry was done by using an anti-
LSD1 antibody (catalog No. 100–1762, Novus Biologi-
cals, Littleton, CO, diluted 1:250). The slides were scored
independently by two experienced pathologists (NS and
RB) according to the semi-quantiative scoring system
suggested by Remmele and Stegner [17] considering
staining intensity and percentage of positive cell nuclei.
The staining intensity was described by scores between 0
and 3 (0 = no reaction, 1 = low, 2 =moderate, 3 = strong).
Accordingly, the number of positive cell nuclei was
counted and scored between 0 and 4 (0 = no positive cell
nuclei, 1 = <10% positive cell nuclei, 2 = 10-50% positive
cell nuclei, 3 = 51-80% positive cell nuclei, 4 = > 80%
positive cell nuclei). The product of staining intensity
and percentage of positive cell nuclei resulted in a score
(IRS) between 0 and 12. Each sample was categorised by
this rating score (Table 2).Statistical analysis
SPSS software version 18.0 (SPSS GmbH software,
Zurich, Switzerland) was used for statistical analysis.
Differences were considered statistically significant when
p-values were <0.05. A non-parametrically Kruskal-
Wallis-H-Test was employed to analyse differences in
expression levels. Bonferroni-Holm-procedure was used
for analysing single groups in comparison to each other.Results
LSD1 is expressed in pre-invasive and invasive ductal
breast carcinoma
LSD1 expression has not been analysed in pre-invasive
breast lesions, so far. Therefore we investigated LSD1 in
pre-invasive ductal carcinoma in situ in comparison to
invasive breast cancer.
Using immunohistochemistry we analysed LSD1 expres-
sion in low (Figure 1A), intermediate (Figure 1C) and high
grade ductal carcinoma in situ (Figure 1E) as well as in in-
vasive ductal carcinoma of the breast (Figure 1G). Immuno-
histochemical staining revealed nuclear LSD1 expression
both in pre-invasive and invasive breast cancer epithelial
cells. LSD1 was differently expressed within the pre-
invasive lesions and also in comparison to the pre-invasive
forms with invasive ductal breast carcinoma.
In low grade DCIS (Figure 1B) nuclear LSD1 expression
was heterogeneous and weak (IRS= 4). In intermediate
grade DCIS staining of LSD1 was more intense (IRS= 8)
compared to low grade DCIS (Figure 1D). LSD1 was
abundantly expressed in high grade DCIS (IRS = 12)
(Figure 1F) compared to intermediate and low grade
DCIS. In invasive ductal breast carcinomas nuclear LSD1
staining was as strong as in high grade ductal carcinoma
(IRS = 12) (Figure 1H).
Table 1 Clinicopathological and immunohistochemical parameters in relation to LSD1 immunoreactivity in invasive
ductal breast carcinoma
Variable Categorisation LSD1 immunoreactivity
n analysable lowb abundantb pc
Clinicopathological data:
Tumour stagea
pT1 22 5 17 0.370
pT2 5 2 3
pT3 1 0 1
pT4 1 1 0
unknown 3
Lymph node statusa
pN0 16 1 15 0.010
pN1-3 9 5 4
unknown 7
Histological grade
G1 2 0 2 0.010
G2 16 1 15





negative (IRS 0–2) 10 6 4 0.004
positive (IRS 3–12) 22 2 20
Progesterone receptor status
negative (IRS 0–2) 14 6 8 0.090
positive (IRS 3–12) 18 2 16
HER2 status
weak (0-2+) 26 7 19 1.0
strong (3+) 6 1 5
aAccording to UICC: TNM Classification of Malignant Tumours (7th edition). Sobin LH, Gospodarowicz MK, Wittekind CH (eds) Wiley-Blackwell, Oxford 2009.
bLSD1 immunoreactivity: low= IRS 0–9, abundant = IRS 10–12.
cFisher’s exact test (two-sided), bold face representing significant data (P <0.05).
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from pre-invasive to invasive ductal breast carcinoma
In statistical analysis the median of LSD1 expression level
(IRS) was significantly increased during tumour progres-
sion from pre-invasive to invasive ductal breast carcinoma
(low grade DCIS=8, intermediate grade DCIS=10, high
grade DCIS=12, invasive ductal breast carcinoma=12)
(p <0.05, Kruskall-Wallis-H-test) (Table 2, Figure 2).Table 2 LSD1 expression (median IRS) in DCIS and IDC
Tissue n LSD1 expression (median IRS)
low grade DCIS 27 8
intermediate grade DCIS 30 10
high grade DCIS 31 12
IDC 32 12Analysing single groups in comparison to each other we
found that LSD1 was significantly overexpressed in high
grade DCIS versus low grade DCIS (p <0.001). Differences
were also statistically significant between low/intermediate
DCIS and high grade DCIS (p <0.032), but also between
low/intermediate DCIS and invasive ductal breast carcin-
oma (p <0.001). Consistently, statistical significance of
LSD1 expression was also reached between low grade
DCIS and invasive ductal carcinoma (p <0.0001) and low
grade DCIS versus high grade DCIS/invasive ductal car-
cinoma (p <0.0001) (Bonferroni-Holm-procedure).
Statistical correlation of LSD1 expression in invasive
ductal breast carcinoma
LSD1 expression was correlated with clinicopathological
and immunohistochemical parameters in invasive ductal
breast carcinoma. LSD1 expression was significantly
Figure 1 Immunohistochemical expression of LSD1 in pre-invasive and invasive ductal breast carcinoma. (A, B) Low grade DCIS shows
weak nuclear LSD1 expression (IRS = 4). (C, D) In intermediate grade ductal carcinoma in situ LSD1 expression is more intense (IRS = 8) than in low
grade ductal breast cancer. (E, F) In high grade ductal carcinoma in situ LSD1 expression is more abundant (IRS = 12) compared with low grade
and intermediate grade ductal carcinoma in situ. (G, H) In invasive ductal breast carcinoma LSD1 expression is as strong as in high grade ductal
carcinoma (IRS = 12). Magnification A-H: 100x.
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and with the oestrogen receptor status. There was no
siginificant correlation with tumour stage, progesterone
receptor status and Her2 expression (Table 1).
Discussion
LSD 1 is a member of monoaminoxidase enzymes with an
important role in controlling gene expression by histone
modification [5]. In accordance with the perceived role ofLSD1 in cell proliferation, significant expression of LSD1
has been reported in diverse human tumour entities, in-
cluding breast cancer. Until now, LSD1 expression has
not been analysed in pre-invasive breast cancer lesions,
so far. In this study we developed a first systematic expres-
sion analysis of LSD1 in pre-invasive (n= 88) and invasive
(n= 32) breast carcinoma.
Using immunohistochemistry we here show that LSD1
is also expressed in pre-invasive ductal neoplasias of the
Figure 2 Elevated expression of LSD1 during tumour progression. A significant difference in expression during tumour progression from
ductal carcinoma in situ (low, intermediate and high grade) to invasive ductal breast cancer was detected (p <0.05, Kruskall-Wallis H-test).
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crease of LSD1 expression during tumour progression
from low, intermediate and high grade ductal carcinoma
in situ to invasive ductal breast carcinoma (p <0.05).
Our results implicate that LSD1 could play a key role in
breast cancer development. So upregulation of LSD1
may be an early tumour promoting event in breast car-
cinoma. This is supported by the work of Bradley et al.
[15] showing the dynamic movement of LSD1 from the
nuclear periphery into the nucleus after carcinogen
treatment in human mammary epithelial cell lines. Fur-
thermore increased LSD1 expression levels were found
in increasing carcinogen treated human mammary epi-
thelial cell lines compared to non-treated controls. They
concluded that upregulation of LSD1 and localisation
into the nucleus are mechanisms that are responsible for
demethylation of histone H3 (Lys4) by LSD1 affecting
genes like p57kip2, a cyclin-dependent kinase inhibitor,
which is known to be essential in tumourgenesis of
breast cancer cells. It is supposed that LSD1 forms com-
plexes with different co-factors and depending on the
promoter context it has a gene activating or repression
function [1]. A recent study by Scoumanne et al. [6] ana-
lysed the role of LSD1 in the human malignant breast
cancer cell line MCF7. They found out that LSD1 down-
regulation decreased the number of proliferating breast
cancer cells. Even though the concrete mechanism in
which LSD1 is linked to cancer development has not
been fully examined, it has been shown that high LSD1
expression is a characteristic feature of cancer cells.Consistent with these data, we detected high expres-
sion levels of LSD1 in invasive ductal breast carcinoma
which supports the results of a study by Lim et al. [13]
showing abundant LSD1 expression in invasive breast
cancer, as well. In conclusion our data imply a positive
association between LSD1 overexpression and progres-
sion, proliferation as well as increasing invasiveness of
breast cancer cells.
However, in our collective of invasive ductal breast car-
cinoma the inverse correlation of LSD1 expression with
lymph node status, histological grade and oestrogen re-
ceptor status may be due to a inhomogeneous and rela-
tively small group size of invasive breast carcinoma
specimens because this study was not constructed to val-
idate LSD1 expression in invasive breast carcinoma as it
was already analysed in a previous work by Lim et al.
[13]. Furthermore, our collective of invasive ductal breast
carcinomas consists mainly of tumours with small
tumour size accordingly pT1 tumours whereas Lim et al.
[13] analysed more tumours of a higher stage respectively
pT2 to pT4 invasive breast carcinomas. Nevertheless, the
association between LSD1 expression and oestrogen re-
ceptor status has to be further investigated and validated
in greater cohorts of invasive breast carcinomas.
In addition LSD1 could be an interesting target mol-
ecule in the treatment of breast carcinoma. Usually,
DCIS treatment involves breast conserving surgery by
local tumour excision or mastectomy depending on free
margins to reduce the risk of ipsilateral recidive. Supple-
mental radiation is part of adjuvant therapeutic regime
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guidelines for the use of hormone therapy or Trastuzu-
mab, a monoclonal antibody, for patients with (human
epidermal growth factor) HER 2 positive DCIS [19-22].
Boughey et al. [19] suggested that anti-hormone therapy
should be part of adjuvant therapy regime in oestrogen
receptor positive DCIS and the use of Trastuzumab for
DCIS was seen as an option which needs to be more
specified in future. Nonetheless, it was shown by clinical
evidence that only patients with positive oestrogen
receptor status responded to anti-hormone treatment
and a subgroup of patients developed resistance after
extended treatment.
Therefore there is a need for alternative drug treat-
ment in case of resistance to anti-oestrogens. With re-
gard to offering other suitable options of breast cancer
therapy in connection with other eligible targets, LSD1
may be such a target mark as LSD1 inhibitors were dis-
cussed as novel breast cancer therapeutics [13].
Because of its structural analogy with monoaminoxi-
dases, LSD1 was shown to be inhibited by nonspecific
monoaminoxidase inhibitors like tranylcypromine [23].
In a previous work of Lee et al. [23] tranylcypromine
was found to inhibit embryonal carcinoma cells. There-
fore tranylcypromine was discussed as a possible novel
anti-cancer target referring to breast cancer, as well. In
concordance with this, Lim et al. [13] showed inhibition
of LSD1 in breast cancer cells in vitro by tranylcypro-
mine and clorgyline, a selecitve monoaminoxidase in-
hibitor, leading to inhibitory effect on LSD1 and reduced
growth of the breast cancer cell lines MCF7, T47D,
MDA-MB 453 and MDA-MB 231.
Conclusions
In the future LSD1 detection may be an early identifica-
tion marker of breast cancer and a potential target for
early therapeutic strategies. However, in our collective of
invasive ductal breast carcinoma the inverse correlation
of LSD1 expression with oestrogen receptor status may
be due to a inhomogeneous and relatively small group
size of invasive breast carcinoma specimens mainly con-
sisting of pT1 tumours [24]. Further studies are under-
way to analyse the expression and function of LSD1 in a
larger cohort of breast cancer specimens including
patients` survival data to evaluate the prognostic rele-
vance of LSD1 in breast carcinoma.
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